Aclaris Therapeutics Inc (ACRS)

08:55 AM

LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional

08:55 AM

Jul 22, 2025

Aclaris Therapeutics Inc. Stock Analysis and ForecastTremendous financial leverage - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What drives Aclaris Therapeutics Inc. stock priceDynamic growth stocks - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

How Aclaris Therapeutics Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser

Jul 22, 2025

Jul 22, 2025

Is Aclaris Therapeutics Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about Aclaris Therapeutics Inc. stockPhenomenal trading returns - jammulinksnews.com

Jul 22, 2025

Jul 15, 2025

Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser

Jul 15, 2025

Jul 15, 2025

What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025

Jul 15, 2025

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey

Jul 15, 2025

Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025

Jul 12, 2025

Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Jul 12, 2025

Jul 11, 2025

Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st

Jul 11, 2025

Jul 10, 2025

Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World

Jul 10, 2025

Jul 07, 2025

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 07, 2025

Jul 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jul 07, 2025

Jun 30, 2025

Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada

Jun 30, 2025

Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com

Jun 30, 2025

Jun 30, 2025

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire

Jun 30, 2025

Jun 30, 2025

Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan

Jun 30, 2025

Jun 30, 2025

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes By Investing.com - Investing.com UK

Jun 30, 2025

Jun 27, 2025

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - The Manila Times

Jun 27, 2025

Jun 26, 2025

Aclaris Therapeutics to Present at H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025 - Nasdaq

Jun 26, 2025

Jun 26, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 26, 2025

Jun 25, 2025

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN

Jun 25, 2025

Jun 24, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Given Outperform Rating at Wedbush - Defense World

Jun 24, 2025

Jun 19, 2025

Assenagon Asset Management S.A. Purchases 284,191 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jun 19, 2025

Jun 15, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World

Jun 15, 2025

Jun 12, 2025

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st

Jun 12, 2025

Jun 11, 2025

Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa

Jun 11, 2025

Jun 11, 2025

Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia

Jun 11, 2025

Jun 11, 2025

Bank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jun 11, 2025

Jun 10, 2025

Vitiligo Drugs Market Exclusive Report with Detailed Study Analysis | Dermavant Sciences, Aclaris Therapeutics - newstrail.com

Jun 10, 2025